What should be the blood pressure target for diabetic patients?

Current Opinion in Cardiology

Volumn 26, Issue 4, 2011, Pages 308-313

  Elliott, William J ^a  

^a Pacific Northwest University of Health Sciences   (United States)

Author keywords

blood pressure goal; evidence based medicine; hypertension guidelines

Indexed keywords

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE; TARGET VARIABLE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERTENSION; META-ANALYSIS AS TOPIC;

EID: 79958850133     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328347d695     Document Type: Review

References (26)

1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157:2413-2446.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. Hypertension 2003; 42:1206-1252. (Pubitemid 37553153)
3. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A Scientific Statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761-2788.
4. Grundy SM, Cleeman JI, Merz CNB, et al., for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110:227-239.
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
6. Raikou M, Gray A, Briggs A, et al. Cost-effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. U.K. Prospective Diabetes Study Group. BMJ 1998; 317:720-726.
7. Elliott WJ, Weir DR, Black HR. Cost-effectiveness of lowering treatment goal of JNC VI for diabetic hypertensives. Arch Intern Med 2000; 160:1277-1283. (Pubitemid 30252773)
8. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002; 287:2542-2551.
9. Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol 2009; 54:1827-1834.
10. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762. (Pubitemid 28269185)
11. American Diabetes Association. Standards of medical care in diabetes: 2011. Diabetes Care 2011; 34 (Suppl 1):S11-S61. The American Diabetes Association still recommends a BP target of less than 130/80 mmHg, despite the release and publication of the ACCORD trial results 9 months earlier.
12. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
13. Wright JT Jr, Bakris GL, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431. (Pubitemid 35340538)
14. Estacio RO, Jeffers BW, Gifford N, Schrier RW. The effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl 2):B54-B64. (Pubitemid 30185779)
15. Schrier R, Estacio R, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy, and strokes. Kidney Int 2002; 61:1086-1097. (Pubitemid 34175478)
16. Turnbull F, Neal B, Algert C, et al., for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410-1419.
17. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009; 3:CD004349.
18. Arguedas JA. Blood pressure targets: are clinical guidelines wrong? Curr Opin Cardiol 2010; 25:350-354. Updated systematic review and meta-analysis of lower BP targets for any and all hypertensive patients, suggesting that there is no clinical trial evidence to support recommendations of guidelines that call for lower-than-usual BPs. However, it concludes with the statement that the authors are working on subgroup metaanalyses to examine the issue in diabetic patients and individuals with either chronic kidney disease or heart disease.
19. JATOS Study Group. Principal results of the Japanese Trial to Assess Optimal Systolic blood pressure in elderly hypertensive patients. Hypertens Res 2008; 31:2115-2127.
20. Verdecchia P, Staessen JA, Angeli F, et al., for the Cardio-Sis Investigators. Usual versus tight control of systolic blood pressure in nondiabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374:525-533.
21. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011; 154:541-548. The most recent review of clinical trial data in chronic kidney disease, showing no significant benefit of a lower-than-usual BP, with the possible exception of patients with proteinuria.
22. Roger VL, Go AS, Lloyd-Jones D, et al. Heart and stroke statistics: 2011 update - a report from the American Heart Association. Circulation 2011; 123:e18-e209. The most recent national statistics on incidence, prevalence, mortality burden, morbidity, and cost of many aspects of heart disease (including diabetes).
23. Gerstein HC, Miller ME, Byington RP, et al., for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
24. Ginsberg HN, Elam MB, Lovato LC, et al., for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574.
25. Cushman WC, Evans GW, Byington RP, et al., on behalf of The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585. The definitive clinical trial examining the possible cardiovascular benefits of a lower-than-usual BP goal (<120mmHg systolic) compared with the 'usual and customary' (<140mmHg systolic). The results do not support more intensive lowering of BP to prevent cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
26. Cushman WC, Grimm RH Jr, Cutler JA, et al.; for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99 (Suppl):44i-55i.